Investment Rating - The report maintains an "Outperform" rating for Innovent Biologics [2] Core Insights - Innovent Biologics achieved total revenue of RMB 13.0 billion in FY25, representing a year-on-year growth of 38%, with product sales revenue reaching RMB 11.9 billion, up 45% [3][15] - The company turned a net profit attributable to shareholders of RMB 810 million in FY25, compared to a loss of approximately RMB 100 million in the previous year [3][15] - The gross margin improved to 86.5%, an increase of 2.6 percentage points year-on-year [3][15] - The report highlights strong organic sales growth driven by the oncology franchise and the expansion of the product portfolio, with multiple products included in the National Reimbursement Drug List (NRDL) expected to further boost sales in 2026 [4][16] - Out-licensing revenue of RMB 957 million was recognized in FY25, with significant upfront payments from collaborations with Roche and Takeda expected to be progressively recognized in the financial statements from 2026 onward [5][17] - The core asset IBI363 (PD-1/IL-2) is advancing smoothly, with three assets entering global Phase III clinical trials, estimated to have a combined addressable market exceeding USD 60 billion [7][19] - The early-stage pipeline shows strong global competitiveness, with 11 new molecules advanced into clinical development, expected to yield early data in 2026-2027 [9][20] - The target price is adjusted to HKD 107.40 based on a DCF model, reflecting an increase in revenue and net profit forecasts for 2026 and 2027 [10][21]
信达生物（01801）：25年业绩回顾：创新产品稳健放量，利润端实现扭亏，研发管线布局全面